Aug 30 (Reuters) - CogState Ltd (CGS) :
- 1H23 CLINICAL TRIALS REVENUE EXPECTED TO BE CONSISTENT WITH 2H22
- CLINICAL TRIALS REVENUE FOR 2H23 WILL VARY WITH LEVEL OF SALES CONTRACTS AND THEREFORE UNABLE TO BE ACCURATELY FORECAST AT THIS TIME
- FY23 HEALTHCARE REVENUE AND SEGMENT CONTRIBUTION EXPECTED TO BE CONSISTENT WITH FY22
- SEES FY23 EBIT, BASED ON CURRENT REVENUE FORECAST, EXPECTED TO BE AT BOTTOM END OF TARGET RANGE OF 20% - 24% OF REVENUE
- SEES FY23 OPERATING CASHFLOW OF ABOUT 75% OF EBITDA
- FY23 EBITDA TARGETED TO BE IN RANGE OF 27% - 29% OF REVENUE
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.02 |
Change
0.020(1.00%) |
Mkt cap ! $345.8M | |||
| Open | High | Low | Value | Volume |
| $2.00 | $2.07 | $1.98 | $411.8K | 203.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 7634 | $2.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.04 | 401 | 2 |
View Market Depth
| Last trade - 14.08pm 19/09/2025 (20 minute delay) ? |
| CGS (ASX) Chart |